BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.
/Bio-Techne%20ground%20sign%20outside%20of%20the%20office%20in%20San%20Jose%2C%20California%2C%20USA%20-%20June%208%2C%202023_%20By%20JHVEPhoto.jpeg)
Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.
/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.
As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.
SpaceX IPO buzz faded as AI volatility, hotter inflation, and a shortened trading week shifted investor focus toward earnings season
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.
Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.
/Incyte%20Corp_%20logo%20and%20bar%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.